Pal-GQPR, Rigin
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Palmitoyl Tetrapeptide-7 is a cosmetic peptide ingredient designed to reduce skin inflammation, making it the anti-inflammatory half of the Matrixyl 3000 combination. Developed under the trade name Rigin, it targets the inflammatory signalling that contributes to skin ageing. It has no pharmaceutical approval.
No published studies found on PubMed.
Palmitoyl Tetrapeptide-7 has no pharmaceutical authorisation. It is used as a cosmetic ingredient, primarily as a component of Matrixyl 3000 (#135). A standalone study (17 subjects) reported improvements in skin firmness and wrinkle reduction.
Its anti-inflammatory mechanism provides a different approach to skin ageing compared to collagen-stimulating peptides. It is a topical cosmetic ingredient.
Research suggests Pal-GQPR suppresses the inflammatory signalling molecule IL-6, which increases in skin with age and UV exposure and contributes to collagen breakdown. In vitro studies report up to 86% suppression of UV-induced IL-6 production. The anti-inflammatory approach to skin ageing is biologically plausible but has not been confirmed through pharmaceutical-grade clinical trials.
Research suggests a small standalone study (17 participants) reported improvements in skin firmness and wrinkle reduction. Laboratory studies show suppression of an inflammatory signalling molecule (IL-6) in UV-exposed cells, but this has only been demonstrated in cell cultures, not in human skin. All data are manufacturer-sponsored with small sample sizes. No large independent trials exist. It is a topical cosmetic ingredient.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
